title: FDA perspectives on supplement use by patients on antithrombotic therapy.
authors.affiliation: Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, HFD-870, Rockville, MD 20857, USA. KIMMYO@cder.fda.gov
authors.forename: Myong-Jin
authors.initials: MJ
authors.lastname: Kim
mesh_terms: D019587:Dietary Supplements / Q000592:standards*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004347:Drug Interactions; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D033161:Government Regulation; D006801:Humans; D007880:Legislation, Drug; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D005343:Fibrinolytic Agents